See more : OmniAb, Inc. (OABI) Income Statement Analysis – Financial Results
Complete financial analysis of Candel Therapeutics, Inc. (CADL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Candel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Films, Inc. (AMFL) Income Statement Analysis – Financial Results
- Eros Media World Plc (EMWP) Income Statement Analysis – Financial Results
- Anchorstone Holdings Limited (1592.HK) Income Statement Analysis – Financial Results
- Tandy Leather Factory, Inc. (TLF) Income Statement Analysis – Financial Results
- Repco Home Finance Limited (REPCOHOME.NS) Income Statement Analysis – Financial Results
Candel Therapeutics, Inc. (CADL)
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 125.00K | 125.00K | 125.00K | 125.00K |
| Cost of Revenue | 23.98M | 987.00K | 232.00K | 0.00 | 6.61M |
| Gross Profit | -23.98M | -862.00K | -107.00K | 125.00K | -6.48M |
| Gross Profit Ratio | 0.00% | -689.60% | -85.60% | 100.00% | -5,185.60% |
| Research & Development | 24.51M | 20.79M | 15.18M | 8.75M | 6.61M |
| General & Administrative | 13.72M | 14.06M | 10.67M | 5.18M | 2.56M |
| Selling & Marketing | 687.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.41M | 14.06M | 10.67M | 5.18M | 2.56M |
| Other Expenses | -24.51M | -48.00K | -1.08M | -624.00K | -571.00K |
| Operating Expenses | 14.41M | 34.80M | 24.78M | 13.31M | 8.59M |
| Cost & Expenses | 38.39M | 34.80M | 24.78M | 13.31M | 8.59M |
| Interest Income | 0.00 | 490.00K | 53.00K | 111.00K | 1.07M |
| Interest Expense | 514.00K | 490.00K | 53.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 960.00K | 987.00K | 232.00K | 91.00K | 43.00K |
| EBITDA | -37.43M | -17.32M | -25.49M | -13.72M | -8.20M |
| EBITDA Ratio | 0.00% | -40,835.20% | -19,534.40% | -6,792.00% | -6,063.20% |
| Operating Income | -38.39M | -34.72M | -25.73M | -13.81M | -9.04M |
| Operating Income Ratio | 0.00% | -27,777.60% | -20,580.80% | -11,048.00% | -7,229.60% |
| Total Other Income/Expenses | 452.00K | 15.93M | -10.40M | -3.87M | 797.00K |
| Income Before Tax | -37.94M | -18.79M | -36.12M | -17.68M | -8.24M |
| Income Before Tax Ratio | 0.00% | -15,035.20% | -28,899.20% | -14,144.00% | -6,592.00% |
| Income Tax Expense | 0.00 | -15.93M | 53.00K | 4.49M | -226.00K |
| Net Income | -37.94M | -2.87M | -36.18M | -22.17M | -8.01M |
| Net Income Ratio | 0.00% | -2,292.80% | -28,941.60% | -17,739.20% | -6,411.20% |
| EPS | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| EPS Diluted | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| Weighted Avg Shares Out | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
| Weighted Avg Shares Out (Dil) | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
NEEDHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced initial positive interim survival and immunological...
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
NEEDHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Nature published results from the...
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the Company will present three posters at the...
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
NEEDHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced updated activity data from its ongoing,...
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD,...
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter...
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD,...
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that, in the second quarter of...
Candel Therapeutics Upcoming Investor Conference Participation for November
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the...
Candel Therapeutics Upcoming Investor Conference Participation
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate...
Source: https://incomestatements.info
Category: Stock Reports